Aquestive Therapeutics, Inc. (AQST) shares jumped 16% on Mar 15 after the company achieved the primary and secondary endpoints in the two-part phase III pivotal pharmacokinetic clinical study of Anaphylm (epinephrine) Sublingual Film to treat severe allergic reactions. The stock price surge was also likely boosted by findings from the FDA Type C meeting.AQST’s Anaphylm is a non-invasive oral epinephrine product candidate. It has the potential to offer greater convenience of use compared with autoinjectors, ...